Impact of the CYP3A5 genotype on midazolam pharmacokinetics and pharmacodynamics during intensive care sedation

Information is lacking on whether the CYP3A5 genotype affects the disposition and effects of midazolam during the long-term intensive care sedation of patients. This study was undertaken to estimate whether the CYP3A5 genotype can explain a relevant portion of pharmacokinetic interindividual variabi...

Full description

Saved in:
Bibliographic Details
Published in:European journal of clinical pharmacology 2007-12, Vol.63 (12), p.1129-1133
Main Authors: Fromm, Martin F, Schwilden, Helmut, Bachmakov, Iouri, König, Jörg, Bremer, Frank, Schüttler, Jürgen
Format: Article
Language:English
Subjects:
Aged
Conscious Sedation
Critical Care
Cytochrome P-450 CYP3A - genetics
Cytochrome P-450 CYP3A - pharmacology
Drug Monitoring - methods
Drug therapy
Genotype
Genotype & phenotype
Humans
Hypnotics and Sedatives - blood
Hypnotics and Sedatives - pharmacokinetics
Hypnotics and Sedatives - pharmacology
Intensive care
Midazolam - analogs & derivatives
Midazolam - blood
Midazolam - pharmacokinetics
Midazolam - pharmacology
Middle Aged
Pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Information is lacking on whether the CYP3A5 genotype affects the disposition and effects of midazolam during the long-term intensive care sedation of patients. This study was undertaken to estimate whether the CYP3A5 genotype can explain a relevant portion of pharmacokinetic interindividual variability. We determined the CYP3A5 genotype in 71 Caucasian patients who underwent long-term sedation during intensive care treatment. We then assessed the relation between the genotype and both the plasma concentrations of midazolam and 1'-OH-midazolam in 645 plasma samples and the simultaneously estimated Ramsay sedation score, both of which were recorded during routine midazolam drug monitoring. Eight patients had the CYP3A5*1/*3 genotype and 63 patients the CYP3A5*3/*3 genotype. The concentration-dose ratio [C/D; plasma concentration of midazolam (ng/ml) divided by the rate of infusion (mg/h); expressed as the mean (95% confidence interval)] was 87.4 (70.8, 108.9) for the *3/*3 patients and 79.0 (48.9, 129.0) for *1/*3 patients. The corresponding data for infusion rate (IR; in mg/h), Ramsay score (RS) and the ratio 1'-OH-midazolam concentration/midazolam concentration (ROH) for *3/*3 and *1/*3 patients were IR 7.4 (6.2, 8.6) vs. 11.4 (4.9, 17.9), RS 5.4 (5.2, 5.6) vs. 5.3 (4.2, 6.0) and ROH 0.11 (0.09, 0.13) vs. 0.17 (0.11, 0.26), respectively. The CYP3A5*1/*3 genotype did not lead to an apparently lower midazolam concentration/dose ratio or Ramsay score values. As the present sedation procedure during intensive care therapy may be described as a physician closed-loop titration towards Ramsay scores of 4 +/- 1, our data do not indicate that prior determination of the genotype will result in better care or economic savings.
ISSN:0031-6970
1432-1041
DOI:10.1007/s00228-007-0365-6